23% Weight Loss! Will an Amylin Beat Retatrutide? EASD 2026
The Downsized — 23% Weight Loss! Will an Amylin Beat Retatrutide? EASD 2026
Channel: DOWNSIZED · Our label: Patient-experience channel — GLP-1 journey, daily · Source: youtube.com/watch?v=VAtI6ifRXpc
What this video covers
23% weight loss about 54 pounds in under a year. Tzepide plus a new hormone in people with type 2 diabetes and it topped retatride. My name is Christopher Durham and welcome to the downsized. If you’re new here, my wife Lorraine and I are a regular suburban couple who started treating our obesity with tepatide in September of 2023.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Phase three trials are much bigger, and they’re what the FDA decides on.
- Lyanna Billings of Endeavor Health in Illinois who summed up the reason for the study simply.
- That means we can see what adding amalin did inside the same study instead of comparing separate trials.
- Kagrama could be first possibly before the end of this year if the FDA approves it for the drugs from Milan and none of these companies have given an approval date.
- Its latest stage trials started in 2023 and Lily plans to file for approval in 2027.
- Perhaps what’s more exciting is the potential of one day having a portfolio of drugs even as individual pieces an amalin a GLP1 GIP a glucagon that your doctor could write a prescription built just for you.
Read next
- GLP-1 class — more videos
- Tirzepatide — more videos
- Retatrutide — more videos
- All videos from this channel
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.